4//SEC Filing
Griffin Stephen D. 4
Accession 0001171843-25-001533
CIK 0000898437other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 5:16 PM ET
Size
8.6 KB
Accession
0001171843-25-001533
Insider Transaction Report
Form 4
Griffin Stephen D.
EVP, CFO & COO
Transactions
- Award
Restricted Stock Unit
2025-03-14+18,672→ 18,672 totalExercise: $0.00→ Common Stock (18,672 underlying) - Award
Restricted Stock Unit
2025-03-14+38,473→ 38,473 totalExercise: $0.00→ Common Stock (38,473 underlying)
Footnotes (2)
- [F1]Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026.
- [F2]Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 18,672 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold.
Documents
Issuer
Anika Therapeutics, Inc.
CIK 0000898437
Entity typeother
Related Parties
1- filerCIK 0001831125
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 5:16 PM ET
- Size
- 8.6 KB